Table 1 Baseline demographics of patients presented at the Molecular Tumor Board (N = 715 unique patients)a.

From: Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Period

December 2012–September 2018

Number of meetings

200

Age

Median, 61 years; Range, 3–92 years

Gender, N (%)

Men, 295 (41.3%); Women, 420 (58.7%)

Number of physicians who presented ≥1 case

58

Diagnosis, N (%)

 

Breast cancer

129 (18.0)

Colorectal cancer

87 (12.2)

Hematologic malignancies

51 (7.1)

Gastroesophageal cancer

51 (7.1)

Pancreatic cancer

48 (6.7)

Biliary cancer

37 (5.2)

Lung cancer

36 (5.0)

Gynecologic cancer

36 (5.0)

Other GI malignanciesb

33 (4.6)

Sarcoma

32 (4.5)

Bladder/Ureter cancer

20 (2.8)

Head and neck cancer

19 (2.7)

Hepatocellular carcinoma

18 (2.5)

Neuroendocrine malignancies

17 (2.4)

Prostate cancer

13 (1.8)

CNS malignancies

12 (1.7)

Thyroid cancer

5 (0.7)

Other malignancies

71 (9.9)

  1. aAmong the 858 presented patients, 99 patients were presented more than once. Only the first records were included in the analysis. Forty-four patients without complete discussion record were excluded (Supplementary Fig. 1). Only patients in face-to-face Molecular Tumor Board meetings were included.
  2. bOther GI malignancies include appendiceal adenocarcinoma (N = 27), duodenal cancer (N = 4) and small bowel adenocarcinoma (N = 2).
  3. CNS central nervous system, GI gastrointestinal.
Back to article page